ASCENDIS HEALTH LIMITED - Trading Statement

Trading Statement

ASCENDIS HEALTH LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2008/005856/06)
Share code: ASC ISIN: ZAE000185005
(“Ascendis” or “the Company”)

TRADING STATEMENT

In terms of paragraph 3.4(b) of the JSE Limited’s Listings Requirements, Ascendis shareholders are
hereby advised that the Company’s financial results for the six months ended 31 December 2016 are
expected to be more than a 20% change from the previous corresponding period.

The table below illustrates the ranges anticipated against the comparative period:

                                             6 months ended       6 months ended      % increase/
                                               31 December          31 December       (decrease)
                                                   2016                 2015
 Normalised Headline Earnings                R298m – R315m             R151m         97% – 109%

 Normalised Headline Earnings per share        72 – 76 cents          56 cents        29% – 36%
 (“NHEPS”)
 Basic Earnings                              R166m – R178m             R132m          26% – 35%

 Basic Earnings per share (“EPS”)              40 – 43 cents          49 cents       (18)% – (12)%

 Headline Earnings                           R166m – R178m             R131m          27% - 36%

 Headline Earnings per share (“HEPS”)          40 – 43 cents          49 cents       (18)% - (12)%



Notes:
   1. Normalised headline earnings and NHEPS comprise basic earnings adjusted for specific non-
       trading items and once-off costs. Once off costs for the 6 months ended 31 December 2016
       amount to c.R92m, primarily relating to transaction costs, finance and hedging costs for the
       purchase of Remedica and Scitec as announced on SENS on 26 August 2016
       (“Acquisitions”). Accordingly the contributions from the Acquisitions are not consolidated for
       the full period.

   2. The “per share” measures reflect a lower percentage increase than the earnings numbers due
       to the change in weighted average number of shares from c. 270m to 414m due to additional
       shares issued by Ascendis during the course of the six month period ended 31 December
       2016 in connection with the Acquisitions.

The financial information on which this trading statement is based has not been reviewed or reported
on by the Company’s auditors.

Shareholders are advised that the results for the six months ended 31 December 2016 are scheduled
to be released on SENS on 8 March 2017 and presented in Cape Town on 8 March 2017 and
Johannesburg on 9 March 2017.

23 February 2017

Johannesburg

Sponsor
Investec Bank Limited

Date: 23/02/2017 11:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.